Editorial Team Opinion: Let’s be blunt. CRISPR’s success has been so huge it’s blinding everyone to the real story: synthetic biology. Yes, CRISPR has soaked up the attention and funding for a decade, but the next trillion-dollar industries won’t come from just editing genes. They’ll come from engineering biology from the ground up. Investors who are still fixated on CRISPR are admiring a single tree and missing the entire forest. It’s time to completely rethink biotech funding and get serious about the huge, messy, and far more valuable world of synthetic biology. The question is, will traditional VCs wake up before it’s too late?
Key Takeaways
- Investing in foundational synbio platforms (beyond CRISPR) is where the real action is, with projections of 10x returns in the next five years that will blow past traditional biotech.
- A deep tech strategy that works here has to be built on interdisciplinary teams, you need biologists, AI experts, and automation engineers working together to build these systems.
- Companies that can show they have a scalable biomanufacturing process for making sustainable chemicals and materials are going to pull in massive capital, with the market expected to hit $300 billion by 2030.
- Governments and private funds have to get serious about setting up dedicated accelerators for synbio startups to get them out of the lab and into the market.
- Putting money into computational biology tools and automated lab hardware is the only way to shorten development time and de-risk these early-stage synbio companies.
The Narrowing Lens of CRISPR Dominance
For years, CRISPR has been the celebrity of biotech. It’s a fantastic tool that delivers on its promise of precise gene editing. That ease of use created a gold rush, with a Reuters report tallying over $15 billion in global investment for CRISPR tech between 2018 and 2023 for everything from gene therapies to better crops. This laser focus, driven by clear therapeutic payoffs, has warped how people see the entire field of biotechnology. I see investors, especially those without a science team on staff, defaulting to CRISPR-centric companies because it’s what they know. It’s a comfortable story. They get “gene editing.” What they don’t get is designing a whole new biological pathway or engineering a microbe to pump out a complex molecule at industrial scale. And that’s where they’re getting left behind.
I’ve seen it in pitch meetings. Founders with revolutionary biomanufacturing platforms get blank stares because they don’t fit into the neat “gene therapy” or “diagnostics” boxes VCs have been filling for years. The first question is often, “But where’s the CRISPR?” This reveals a complete misunderstanding of what synthetic biology is even about. We’re talking about building biological factories from scratch or rewiring them for entirely new jobs. The problem is that a lot of institutional money is still working from a 2018 playbook, completely missing the tectonic shifts happening in labs and startups right now. The next big thing probably won’t be a simple gene cut, it’ll be a fully designed metabolic network.
Beyond Gene Editing: The True Frontier of Engineered Biology
The next real frontier for biotech money is the wide-open field of synthetic biology. This covers everything from custom-designing enzymes for factories to engineering microbes that eat pollution and produce sustainable fuel or biodegradable plastics. Take a look at cell-free protein synthesis, where you can run biochemical reactions without a living cell, giving you incredible speed and control for making biologics. Or consider directed evolution platforms that can create bespoke enzymes for industrial jobs, blowing past what’s possible with old-school chemical synthesis. These are fundamental shifts in how we make things, treat people, and manage the planet.
A recent World Economic Forum report, done with McKinsey & Company, put a number on it, projecting synbio’s economic impact could hit $30 trillion over the next two decades across almost every sector imaginable. This is about agriculture, energy, and materials science. We’ve got companies engineering microbes to pull carbon dioxide right out of the air. That’s a real shot at tackling climate change. Others are using engineered yeast to produce cannabinoids or vanillin, which is way more sustainable and cheaper than farming them. This stuff isn’t always as flashy as a new gene therapy, but it’s the foundational tech that will support dozens of industries for decades. The investment community has to get its head around that breadth and stop clinging to its genetic scissors.
The Imperative for Deep Tech Investment Strategies
Putting money into synthetic biology means thinking like a deep tech investor. You need patient capital, a stomach for long development cycles, and a tolerance for hard science. The payoff, though, can be massive. A recent Lux Research analysis showed that early-stage synbio companies that make it from the lab to a pilot-scale operation saw their valuations jump an average of 700% in five years. That blows general biotech indexes out of the water. To play in this game, investors need to hire people or get advisors who actually understand metabolic engineering, computational biology, and how to scale a bioprocess. Knowing the market isn’t enough. You have to understand the science.
The pushback I always get is about risk and time. “It takes too long to get to market,” the VCs complain. And yes, regulatory and scale-up problems are real, but the whole field is accelerating. The convergence of biology and computation is changing the game. High-throughput screening, AI-driven strain engineering, and robotic cloud labs are slashing the time and money it takes to get a product ready. For instance, a company using AI to design an enzyme can optimize it in a few months, a process that used to take years of painstaking lab work. If you’re a software investor who doesn’t understand cloud computing, you’re going to get left behind. This is the exact same situation in biotech. This combo of biology and code is de-risking the whole field for anyone smart enough to do their homework.
Building the Ecosystem: A Call to Action for Funding Bodies
To get this done, we need a serious push from all funding sources. Government grants from places like the National Science Foundation (NSF) or Innovate UK are great for early-stage research, but there’s a huge funding gap after that. This “valley of death” is where promising synthetic biology startups go to die. We need a lot more specialized incubators and accelerators (like IndieBio, but more of them) that give startups capital, but also access to expensive lab gear, bioprocess experts, and regulatory help. We also need to see more corporate VCs from the big chemical, pharma, and materials companies get in the game, forming partnerships that create a clear path to market.
On top of that, investors have to get comfortable backing the platform, not just the product. A company with a better way to engineer organisms to produce a whole range of molecules is often a much better long-term bet than a company focused on one drug. In a field moving this fast, the ability to pivot is everything. This requires a real gut-level understanding of the engineering principles at play. The future of manufacturing, sustainability, and medicine depends on our ability to engineer biology. The people who write the checks for this next wave won’t just make a fortune, they’ll be funding solutions to some of our biggest problems. The capital’s there. The strategic vision just needs to catch up.
The post-CRISPR era is here, and it requires a smarter approach to biotech funding. Investors have to look past the gene-editing story and see the enormous power of synthetic biology. The next big wins will come from those who know how to build life, not just edit it. Invest in the builders, and you’re investing in the future.
What’s the real difference between CRISPR and synthetic biology for an investor?
Think of CRISPR as a scalpel for editing existing genes. Synthetic biology is like a full-scale engineering discipline for designing and building new biological systems from scratch. An investment in CRISPR is a bet on a specific tool, while an investment in synthetic biology can be a bet on an entire factory or platform for making new materials, chemicals, or drugs.
Why should biotech funding priorities shift away from just CRISPR?
The funding needs to shift because the biggest opportunities are now elsewhere. While CRISPR got huge investment, that obsession caused VCs to miss the boat on the broader applications of synthetic biology in biomanufacturing, sustainable materials, and agriculture, which represent a much larger potential market than gene editing alone.
What makes it so hard for synbio startups to get funding?
Synbio startups often struggle because their science is complex, the R&D timelines can be long, and they need expensive, specialized labs. Many investors don’t have the in-house scientific expertise to properly vet these companies, so they stick to the simpler, more familiar story of CRISPR-based therapies.
How is AI changing the game for synthetic biology investment?
AI and automation are turbocharging the whole field. They’re making discovery and development much faster and cheaper. Things like AI-powered enzyme design and robotic lab work reduce project timelines from years to months, which significantly de-risks the investment and makes these companies much more attractive.
What kind of funding is most needed to grow the synbio field?
It’s a mix. You need government grants for the basic science, but the real gap is in private capital. We need more venture capital, especially from corporate VCs, and more specialized accelerators and incubators that can provide not just money but also the lab space and expertise to get startups from a great idea to a commercial product.
